Cytokinetics to Present Data Related to Skeletal Muscle Activators at Conference of Society on Sarcopenia, Cachexia and Wasting Disorders

December 4, 2013 12:30 PM EST

South San Francisco, CA, December 4, 2013 **-** Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that two presentations, relating to its fast skeletal muscle troponin activators, are scheduled to be presented at the 7th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders from December 9-11, 2013 in Kobe, Japan.

Presentations at the 7th International Conference of the Society of Sarcopenia, Cachexia and Wasting Disorders:

Date: Tuesday, December 10, 2013
Session Time: 2:00 PM - 3:30 PM (Japan Standard Time)
Session: Drug Treatment Options and Results Update
Title: Fast Skeletal Muscle Troponin Activators and Their Application to Disease - Preclinical Rationale
Presenter: Fady I. Malik, MD, PhD, FACC

Date: Tuesday, December 10, 2013
Session Time: 4:30 PM - 6:00 PM (Japan Standard Time)
Session: Late Breaking Clinical Trials and Biomarker Research
Title: Fast Skeletal Muscle Troponin Activators and their Application to Disease - Clinical Update
Presenter: Fady I. Malik, MD, PhD, FACC

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, *omecamtiv mecarbil*, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide to develop and commercialize *omecamtiv mecarbil* and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing *tirasemtiv*, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. *Tirasemtiv* is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a skeletal muscle activator structurally distinct from *tirasemtiv*, for non-neuromuscular indications. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Joanna L. Goldstein
Manager, Investor Relations & Corporate Communications
(650) 624-3000